MedPath

The predictive value of PET-CT and PET-DW-MRI early during chemoradiotherapy for head and neck cancer

Recruiting
Registration Number
NL-OMON28050
Lead Sponsor
Prof. dr. R. de BreeDepartment of Otolaryngology/ Head and Neck surgeryVU University Medical Center1081 HV Amsterdam+31204443689+31204443688r.bree@vumc.nl
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Squamous cell carcinoma

-Oral cavity, pharynx or larynx

Exclusion Criteria

-Age < 18 years

-Pregnancy

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To investigate the diagnostic value of FDG-PET-CT and DW-MRI (EPI and non-EPI technique) applied 2 weeks after the start of primary chemoradiotherapy for HNSCC to predict locoregional response in the primary tumor and cervical node metastases.
Secondary Outcome Measures
NameTimeMethod
To determine the value of different criteria, related to the primary objective, such as:<br /><br>•FDG uptake level pretreatment (on PET-CT and PET-MRI)<br /><br>•Residual FDG uptake level after 14 days of therapy (on PET-CT and PET-MRI)<br /><br>•Change of FDG uptake (on PET-CT and PET-MRI)<br /><br>•b=1000 signal intensity and ADC level pretreatment (for both EPI- and non-EPI-technique)<br /><br>•Residual b=1000 signal intensity and ADC level after 14 days of therapy (for both EPI- and non-EPI-technique)<br /><br>•Change of b=1000 signal intensity and ADC (for both EPI- and non-EPI-technique)<br>FDG-uptake levels obtained from PET-CT and PET-MRI will be compared (taking into account the different time intervals between FDG-injection and scanning)
© Copyright 2025. All Rights Reserved by MedPath